Operating Income
McKesson Operating Income increased by 32.8% to $2.15B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 35.1%, from $1.59B to $2.15B. Over 4 years (FY 2022 to FY 2026), Operating Income shows an upward trend with a 32.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
Growth in operating income suggests that the core business is becoming more profitable and efficient.
Detailed definition
The profit realized from a business's own operations after deducting operating expenses like wages, depreciation, and co...
Peer comparison
This is a key metric for comparing the fundamental business performance of companies with different tax or debt structures.
operating_incomeHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $568.00M | $539.00M | $298.00M | $633.00M | $1.04B | $1.12B | $1.24B | $980.00M | $1.10B | $951.00M | $642.00M | $1.22B | $1.03B | $578.00M | $1.22B | $1.59B | $1.04B | $1.41B | $1.62B | $2.15B |
| QoQ Change | — | -5.1% | -44.7% | +112.4% | +63.7% | +8.5% | +10.4% | -21.0% | +12.2% | -13.5% | -32.5% | +89.4% | -15.4% | -43.8% | +111.8% | +30.0% | -34.9% | +35.8% | +15.1% | +32.8% |
| YoY Change | — | — | — | — | +82.4% | +108.5% | +316.4% | +54.8% | +6.2% | -15.4% | -48.3% | +24.1% | -6.5% | -39.2% | +90.7% | +30.8% | +0.7% | +143.4% | +32.3% | +35.1% |
Business Segments
| Segment | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q4 '23 | Q2 '24 | Q3 '24 | Q4 '24 |
|---|---|---|---|---|---|---|---|---|
| U.S. Pharmaceutical | $896.00M | $850.00M | $827.00M | $593.00M | $307.00M | $781.00M | $1.08B | $854.00M |
| Medical-Surgical Solutions | $299.00M | $328.00M | $227.00M | $244.00M | $268.00M | $188.00M | $89.00M | $269.00M |
| International | -$37.00M | $136.00M | $57.00M | $66.00M | $126.00M | $90.00M | -$508.00M | $111.00M |
| Prescription Technology Solutions | $120.00M | $136.00M | $231.00M | $238.00M | — | — | — | — |
| Total | $1.12B | $1.24B | $1.10B | $951.00M | $642.00M | $1.03B | $578.00M | $1.22B |
International, Medical-Surgical Solutions, Prescription Technology Solutions, U.S. Pharmaceutical were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Operating Income at Other Companies
Frequently Asked Questions
- What is McKesson's operating income?
- McKesson (MCK) reported operating income of $2.15B in Q1 2026.
- How has McKesson's operating income changed year-over-year?
- McKesson's operating income increased by 35.1% year-over-year, from $1.59B to $2.15B.
- What is the long-term trend for McKesson's operating income?
- Over 4 years (2022 to 2026), McKesson's operating income has grown at a 32.1% compound annual growth rate (CAGR), from $2.04B to $6.21B.
- What does operating income mean?
- The profit earned from core business activities, before accounting for interest and taxes.